This article first appeared on GuruFocus .
-
Consolidated Revenue:INR 39,600 million for Q3 FY26, up 15.1% YoY.
-
India Formulation Sales:INR 12,986 million for Q3 FY26, up 22.1% YoY.
-
North America Revenue:INR 9,706 million for Q3 FY26, including out-licensing income.
-
Europe Revenue:INR 7,963 million for Q3 FY26, up 9.1% YoY.
-
Emerging Markets Revenue:INR 8,119 million for Q3 FY26, up 8.4% YoY.
-
Consumer Care Business Growth:21.5% YoY.
-
Gross Margin:Impacted by product mix, but overall margin supported by operating leverage.
-
Net Cash Position:Company remains net cash positive.
-
Market Share in India:Ranked 13th with a 2.32% market share.
-
Key Therapeutic Rankings in India:2nd in dermatology and respiratory, 4th in cardiac.
-
Warning! GuruFocus has detected 3 Warning Signs with BOM:532296.
-
Is BOM:532296 fairly valued? Test your thesis with our free DCF calculator.
Release Date: February 02, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Glenmark Pharmaceuticals Ltd ( BOM:532296 ) reported a consolidated revenue growth of 15.1% YoY for Q3 FY26, with significant contributions from the India formulation business, which grew by 22.1%.
-
The company launched innovative products such as NEBZMART GFB Smartules and Glenmark AIRZ FB Smartules, marking the world's first nebulized fixed-dose triple therapy for COPD, demonstrating rapid improvement in lung function.
-
Glenmark's Consumer Care business in India showed a strong performance with a 21.5% YoY sales growth, led by flagship brand Candid Powder, which achieved a 17% revenue growth.
-
The North America business reported a revenue increase to INR 9,706 million, with a core business YoY growth of 4.1%, supported by new product launches and ANDA filings.
-
Glenmark's global innovative portfolio, including RYALTRIS, continues to expand, with marketing applications submitted in over 90 countries and commercialization in 52 markets, showing robust performance and market share growth.
Negative Points
-
The company's gross margin was impacted by product and geographical mix, although operating leverage helped maintain overall margins.
-
Glenmark's Middle East/Africa region experienced subdued sales growth due to delays in new product launches.
-
The Europe operations, despite a 9.1% growth, are expected to see only single-digit to low double-digit growth in the medium term due to previous high growth rates.
-
The Monroe manufacturing facility in North Carolina, although receiving a positive EIR from the US FDA, will take time to reach full commercial production, with an operating break-even expected in about four years.
-
Glenmark's working capital management remains a focus, with initiatives to reduce debtor days and elongate payment cycles, but challenges persist in maintaining a target of 115 days.
Q & A Highlights
Q: Can you quantify the gain from currency depreciation during the quarter? A: Anurag Mantri, Global CFO, explained that currency depreciation contributed to an exceptional item of INR 7.3 crores. However, it's challenging to quantify the exact impact on normal business operations as it integrates into multiple business aspects.
Q: What is the status of the FDA approval for your respiratory products? A: Glenn Saldanha, Executive Chairman and Managing Director, stated that they have had multiple discussions with the FDA and expect an approval soon, potentially by February 24.
Q: How is Glenmark managing its working capital, and what are the targets? A: Anurag Mantri mentioned that they are targeting 115 days of net working capital by March 2026. Initiatives include reducing debtor days through factoring and elongating payment cycles with vendors.
Q: What is the expected trajectory for the Monroe facility after resolving FDA issues? A: Glenn Saldanha indicated that commercial production will start this quarter, with expectations to break even at the operating level in about four years. They plan to file at least three complex injectable products annually from this site.
Q: Can you provide insights into the growth prospects for the European market? A: Glenn Saldanha noted that while Europe has seen strong growth historically, future growth is expected to be in the high single-digit to low double-digit range, driven by new product approvals and launches like WINLEVI.
Q: How are the innovative assets progressing, and what impact will they have? A: Glenn Saldanha highlighted that oncology assets have higher margins and will significantly uplift EBITDA margins starting FY28, with products like abrocitinib and Hungary assets contributing to growth.
Q: What is the planned CapEx for the next fiscal year? A: Anurag Mantri stated that the CapEx is expected to be around INR 800 crores, focusing on ongoing plant expansions and in-licensed products.
Q: How is Glenmark's US business expected to perform in the coming years? A: Glenn Saldanha explained that the US business will be driven by respiratory product approvals and complex injectable filings, with significant contributions expected from FY28 onwards.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
